Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Long-Term Deferred Tax: 2012-2013

  • Arrowhead Pharmaceuticals' Long-Term Deferred Tax fell 1.71% to $40.2 million in Q3 2013 from the same period last year, while for Sep 2013 it was $40.2 million, marking a year-over-year decrease of 1.71%. This contributed to the annual value of $40.2 million for FY2013, which is 1.71% down from last year.
  • According to the latest figures from Q3 2013, Arrowhead Pharmaceuticals' Long-Term Deferred Tax is $40.2 million, which was down 1.71% from $40.9 million recorded in Q3 2012.
  • Arrowhead Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $40.9 million during Q3 2012, with a 5-year trough of $40.2 million in Q3 2013.
  • For the 2-year period, Arrowhead Pharmaceuticals' Long-Term Deferred Tax averaged around $40.5 million, with its median value being $40.5 million (2012).
  • Data for Arrowhead Pharmaceuticals' Long-Term Deferred Tax shows a maximum YoY declined of 1.71% (in 2013) over the last 5 years.
  • Over the past 2 years, Arrowhead Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $40.9 million in 2012, then decreased by 1.71% to $40.2 million in 2013.